Public consultation on applications to be considered by the MSAC (November 2023)

Overview

Consultation is now open for applications that are anticipated to be considered by the Medical Services Advisory Committee (MSAC) on 23-24 November 2023. 

MSAC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application.   

It is anticipated that the below-mentioned applications will proceed to MSAC in July 2023. Consultation input must be received by no later than Friday, 6 October 2023 for it to be considered by MSAC. A consultation survey form is available on the relevant application webpage.

Further information on MSAC’s consultation process is also available on the MSAC website.

Applications scheduled to be considered:

Resubmissions:

1690.1 – Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell to treat refractory or relapsed multiple myeloma

1723.1 – Brexucabtagene autoleucel for adult relapsed or refractory B-precursor acute lymphoblastic leukaemia

New submissions:

1659 - Catheter-based renal denervation for uncontrolled elevated systolic blood pressure

1705 – Structured prenatal risk assessment for preterm preeclampsia

1706 – Angiogenic and anti-angiogenic markers for identification and management of preeclampsia

1716 - Germline BRCA mutation test to detect BRCA1 or BRCA2 mutations in patients with HER2- negative high risk early breast cancer to determine eligibility for PBS-listed olaparib treatment

1727 – Deep brain stimulation for treatment-refractory obsessive compulsive disorder

1734 – Intravascular lithotripsy for the treatment of moderately or severely calcified peripheral artery disease

1740 - N-Terminal-pro Brain Natriuretic Peptide (NT-proBNP) to aid in the diagnosis of patients with suspected heart failure in a non-hospital setting

1758 - Expansion of MBS item numbers 12320 & 12322 for bone mineral density testing to include patients aged 60-69 years

What happens next

Once the consultation closes, submissions will be compiled and considered by MSAC.

Once it has finalised its appraisal of an application for public funding, MSAC publishes a Public Summary Document (PSD). The PSD captures MSAC deliberations and key advice to the Minister, which is generally to either support funding; not support funding; or defer consideration. 

PSDs are generally published approximately three (3) months after the MSAC meeting at which the application was considered. The PSD can be located on the relevant application webpage on the MSAC website.